Mesoblast (MESO) Short-term Investments (2015 - 2016)
Mesoblast (MESO) posted quarterly Short-term Investments of -$805000.0 for Q2 2016, little changed on a QoQ basis from -$805000.0 in Q1 2016.
Mesoblast (MESO) Short-term Investments (2015 - 2016) Analysis & Trends
Mesoblast (MESO) has reported Short-term Investments for 2 consecutive years, with -$805000.0 the latest figure, recorded in Q2 2016.
- Quarterly Short-term Investments changed N/A year-over-year to -$805000.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was -$805000.0 (changed N/A YoY) and the FY2016 annual result came in at -$805000.0, changed N/A from the prior year.
- Short-term Investments held at -$805000.0 in Q2 2016 per MESO's latest filing, from -$805000.0 in the prior quarter.
- Over the last five years, Short-term Investments for MESO reached as high as -$805000.0 in Q4 2015 and fell as low as -$805000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | -805,000.00 |
| Mar 31, 2016 | -805,000.00 |
| Dec 31, 2015 | -805,000.00 |